1. Home
  2. NCRA vs BRTX Comparison

NCRA vs BRTX Comparison

Compare NCRA & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nocera Inc.

NCRA

Nocera Inc.

HOLD

Current Price

$0.97

Market Cap

13.2M

ML Signal

HOLD

Logo BioRestorative Therapies Inc. (NV)

BRTX

BioRestorative Therapies Inc. (NV)

HOLD

Current Price

$1.19

Market Cap

9.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCRA
BRTX
Founded
2002
1997
Country
Taiwan
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Managed Health Care
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.2M
9.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NCRA
BRTX
Price
$0.97
$1.19
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
76.3K
53.0K
Earning Date
04-01-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$14,106,275.00
$383,400.00
Revenue This Year
N/A
$112.14
Revenue Next Year
N/A
$139.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1.70
52 Week Low
$0.75
$0.98
52 Week High
$2.40
$2.55

Technical Indicators

Market Signals
Indicator
NCRA
BRTX
Relative Strength Index (RSI) 38.95 50.62
Support Level $0.82 $1.04
Resistance Level $1.33 $1.16
Average True Range (ATR) 0.13 0.08
MACD 0.00 0.02
Stochastic Oscillator 8.78 78.26

Price Performance

Historical Comparison
NCRA
BRTX

About NCRA Nocera Inc.

Nocera Inc is engaged in the manufacturing of aquaculture equipment, construction of aquaculture facilities, managing and operating aquaculture facilities, and consulting for third-party operators of aquaculture facilities. Its primary business operations consist of the design, development, and production of RASs large-scale fish tank systems, for fish farms along with consulting, technology transfer, and aquaculture project management services to new and existing aquaculture management business services.

About BRTX BioRestorative Therapies Inc. (NV)

BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.

Share on Social Networks: